AQS.V - Aequus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD

Aequus Pharmaceuticals Inc.

200 Granville Street
Suite 2820
Vancouver, BC V6C 1S4
Canada
604-336-7906
http://www.aequuspharma.ca

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. Douglas Glen JanzenChairman, CEO & Pres180kN/A1969
Ms. Ann Fehr CGA, CPAChief Financial Officer96.56kN/A1969
Ms. Anne Michelle Stevens BSc, MHACOO, Corp. Sec. & Director141.8kN/A1981
Mr. Ian Richard BallChief Commercial Officer144kN/AN/A
Dr. Donald Alan McAfeeChief Scientific OfficerN/AN/A1942
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Topiramate and Oxcarbazepine extended-release tablets for the treatment of epilepsy. Its development stage product candidates include AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and irritability associated with autistic disorders, as well as depressive disorders; AQS1303, a transdermal pyridoxine/ doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304 to treat neurological disorders. The company has a collaboration agreement with Scientus Pharma Inc. for the development and commercial supply of specific cannabinoid extracts; and licensing agreement with Supernus Pharmaceuticals, Inc. for the development and commercialization of products for the treatment of central nervous system disorders. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.

Corporate Governance

Aequus Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.